Zasocitinib shows promise as psoriasis treatment
In the treatment of psoriasis, selective inhibition of tyrosine kinase 2 (TYK2) with zasocitinib appears to have superior effects compared with placebo, with greater skin clearance observed over 12 weeks, according to data from a phase 2b study.
